Jack W. Callicutt - Nov 10, 2025 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Role
Chief Financial Officer
Signature
Jack W. Callicutt
Stock symbol
GALT
Transactions as of
Nov 10, 2025
Transactions value $
-$24,167
Form type
4
Date filed
11/12/2025, 04:01 PM
Previous filing
Nov 7, 2025
Next filing
Nov 19, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
CALLICUTT JACK W Chief Financial Officer C/O GALECTIN THERAPEUTICS INC., 4960 PEACHTREE INDUSTRIAL BLVD., STE 240, NORCROSS Jack W. Callicutt 2025-11-12 0001266773

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GALT Common stock Options Exercise $3.72K +1.88K +24.06% $1.98 9.69K Nov 10, 2025 Direct F1
transaction GALT Common stock Sale -$11.3K -1.88K -19.8% $6.02 7.61K Nov 10, 2025 Direct F1, F5
transaction GALT Common stock Options Exercise $1.86K +1.68K +22% $1.11 9.29K Nov 10, 2025 Direct F1
transaction GALT Common stock Sale -$10.1K -1.68K -18.03% $6.03 7.61K Nov 10, 2025 Direct F1, F5
transaction GALT Common stock Options Exercise $2.14K +1.74K +22.8% $1.23 9.35K Nov 10, 2025 Direct F1
transaction GALT Common stock Sale -$10.5K -1.74K -18.57% $6.03 7.61K Nov 10, 2025 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GALT Stock option (right to buy) Options Exercise $0 -1.88K -4.75% $0.00 37.7K Nov 10, 2025 Common stock 1.88K $1.98 Direct F1, F2
transaction GALT Stock option (right to buy) Options Exercise $0 -1.68K -4.23% $0.00 37.9K Nov 10, 2025 Common stock 1.68K $1.11 Direct F1, F3
transaction GALT Stock option (right to buy) Options Exercise $0 -1.74K -3.29% $0.00 51.1K Nov 10, 2025 Common stock 1.74K $1.23 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.
F2 The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023.
F3 The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024.
F4 The options vests as follows: 25% on June 30, 2025, with 25% scheduled to vest on each of December 31, 2025, June 30, 2026, on December 31, 2026.
F5 The shares were sold in multiple transactions at prices ranging from $6.00 to $6.14. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.